pCMV-T7-SpRY-P2A-EGFP (RTW4830) Citations (5)
Originally described in: Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.Walton RT, Christie KA, Whittaker MN, Kleinstiver BP Science. 2020 Apr 17;368(6488):290-296. doi: 10.1126/science.aba8853. Epub 2020 Mar 26. PubMed Journal
Articles Citing pCMV-T7-SpRY-P2A-EGFP (RTW4830)
| Articles |
|---|
Engineered Prime Editors with PAM flexibility.
Kweon J, Yoon JK, Jang AH, Shin HR, See JE, Jang G, Kim JI, Kim Y.
Mol Ther. 2021 Feb 23. pii: S1525-0016(21)00089-7. doi: 10.1016/j.ymthe.2021.02.022.
PubMed
Associated Plasmids |
| Highly efficient A-to-G base editing by ABE8.17 in rabbits. Zhao D, Qian Y, Li J, Li Z, Lai L. Mol Ther Nucleic Acids. 2022 Jan 28;27:1156-1163. doi: 10.1016/j.omtn.2022.01.019. eCollection 2022 Mar 8. PubMed |
Quantification of Genome Editing and Transcriptional Control Capabilities Reveals Hierarchies among Diverse CRISPR/Cas Systems in Human Cells.
Escobar M, Li J, Patel A, Liu S, Xu Q, Hilton IB.
ACS Synth Biol. 2022 Oct 21;11(10):3239-3250. doi: 10.1021/acssynbio.2c00156. Epub 2022 Sep 26.
PubMed
Associated Plasmids |
| Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles. Li S, Du M, Deng J, Deng G, Li J, Song Z, Han H. Acta Biomater. 2022 Dec;154:597-607. doi: 10.1016/j.actbio.2022.10.015. Epub 2022 Oct 13. PubMed |
PAM-flexible genome editing with an engineered chimeric Cas9.
Zhao L, Koseki SRT, Silverstein RA, Amrani N, Peng C, Kramme C, Savic N, Pacesa M, Rodriguez TC, Stan T, Tysinger E, Hong L, Yudistyra V, Ponnapati MR, Jacobson JM, Church GM, Jakimo N, Truant R, Jinek M, Kleinstiver BP, Sontheimer EJ, Chatterjee P.
Nat Commun. 2023 Oct 4;14(1):6175. doi: 10.1038/s41467-023-41829-y.
PubMed
Associated Plasmids |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.